<DOC>
	<DOCNO>NCT00433459</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study different combination chemotherapy regimens compare well work treat young patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether 5-year event-free survival ( EFS ) rate pediatric patient Hodgkin 's lymphoma adequate response 2 course vincristine , etoposide , prednisone , doxorubicin hydrochloride ( OEPA ) ( without radiotherapy ) consistent estimate target EFS rate 90 % . - Compare EFS ( without deterioration ) patient treat procarbazine hydrochloride v dacarbazine ( treatment group 2 3 ) . - Determine treatment outcome standardize risk-adapted relapse strategy patient . Secondary - Determine whether 5-year EFS rate patient Hodgkin 's lymphoma inadequate response 2 OEPA course standard involved-field radiotherapy consistent estimate target EFS rate 90 % . - Determine whether positive positron emission tomography scan plan high-dose chemotherapy autologous stem cell transplantation negative prognostic significance . - Compare effect dacarbazine v procarbazine rate infertility males premature menopause female ( treatment group 2 3 ) . Tertiary - Determine impact real-time central stag response assessment treatment outcome patient . OUTLINE : This randomize , control , parallel-group , open-label , multicenter study . Patients stratify accord stag response assessment ( central vs local ) disease stage ( IA/B IIA [ first-line treatment group 1 ] v I_EA/B , II_EA , IIB , IIIA [ first-line treatment group 2 ] v II_EB , III_E A/B , IIIB , IVA/B [ first-line treatment group 3 ] ) . - First-line treatment group 1 : Patients receive oral prednisone ( prednisolone ) 3 time daily day 1-15 , vincristine IV day 1 , 8 , 15 , doxorubicin hydrochloride IV 1-6 hour day 1 15 , etoposide ( etoposide phosphate ) IV 1-2 hour day 1-5 ( OEPA ) . Treatment repeat every 28 day 2 course absence unacceptable toxicity . Patients assess fludeoxyglucose F 18 positron emission tomography ( ^18FDG-PET ) scan . Patients inadequate response undergo radiotherapy within 35 day completion OEPA . - First-line treatment group 2 : Patients receive OEPA group 1 . After completion OEPA , patient randomize 1 2 treatment arm . - Arm I : Patients receive oral prednisone ( prednisolone ) 3 time daily oral procarbazine hydrochloride 2-3 time day day 1-15 vincristine IV cyclophosphamide IV 1 hour day 1 8 ( COPP ) . - Arm II : Patients receive oral prednisone ( prednisolone ) 3 time daily day 1-15 , dacarbazine IV 15-30 minute day 1-3 , vincristine IV cyclophosphamide IV 1 hour day 1 8 ( COPDAC ) . In arm , treatment repeat every 28 day 2 course absence unacceptable toxicity . Patients assess ^18FDG-PET scan . Patients inadequate response undergo radiotherapy within 35 day completion COPP COPDAC . - First-line treatment group 3 : Patients receive OEPA group 1 . After completion OEPA , patient randomize 1 2 treatment arm . - Arm I : Patients receive COPP arm I group 2 . - Arm II : Patients receive COPDAC arm II group 2 . In arm , treatment repeat every 28 day 4 course absence unacceptable toxicity . Patients assess ^18FDG-PET scan . Patients inadequate response undergo radiotherapy within 35 day completion COPP COPDAC . Patients biopsy-confirmed disease progression OR relapse first-line treatment study protocols DAL-HD 90 , GPOH-HD 95 , GPOHHD 2002 Pilot , similar treatment proceed second-line therapy . Patients stratify accord relapse/progression status ( late relapse first-line treatment group 1 [ second-line treatment group 1 ] v early relapse first-line treatment group 1 , 2 , 3 late relapse first-line treatment group 2 3 [ second-line treatment group 2 ] v disease progression [ second-line treatment group 3 ] ) . Patients undergo ^18FDG-PET scan prior begin second-line therapy . - Second-line treatment group 1 : Patients receive ifosfamide IV 22 hour etoposide IV 1-2 hour oral prednisone three time daily day 1-5 ( IEP ) . Patients receive doxorubicin hydrochloride IV 1-6 hour , bleomycin IV , vinblastine IV , dacarbazine IV 15-30 minute day 22 36 ( ABVD ) . Treatment repeat every 50 day 2 course absence disease progression unacceptable toxicity . After chemotherapy treatment , patient undergo radiotherapy . - Second-line treatment group 2 : Patients receive IEP ABVD group 1 . Autologous stem cell collect course 1 2 IEP/ABVD . After chemotherapy , patient adequate response undergo radiotherapy . Patients inadequate response undergo high-dose chemotherapy comprise carmustine IV 1-2 hour day -7 , etoposide IV cytarabine IV 30 minute twice daily day -6 -3 , melphalan IV 1Â½ hour day -2 . Patients undergo autologous hematopoietic stem cell transplantation ( HSCT ) . Patients undergo ^18FDG-PET scan day 50-54 . Patients ^18FDG-PET scan positive disease undergo radiotherapy . - Second-line treatment group 3 : Patients receive IEP ABVD group 1 . All patient undergo high-dose chemotherapy HSCT group 2 . Patients undergo ^18FDG-PET scan day 50-54 . Patients ^18FDG-PET scan positive disease undergo radiotherapy . After completion study therapy , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 2,150 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm classical Hodgkin 's lymphoma No lymphocytepredominant Hodgkin 's lymphoma Fineneedle biopsy sufficient No prior treatment Hodgkin 's lymphoma except recommended prephase therapy large mediastinal tumor PATIENT CHARACTERISTICS : No known hypersensitivity contraindication study drug No current malignancy No severe concurrent disease ( e.g. , immune deficiency syndrome ) Not pregnant nursing Fertile patient must use effective contraception 1 year completion study treatment No known HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy At least 30 day since prior concurrent investigational drug participation another investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
</DOC>